In our NASH model, we found that treatment with a PPAR agonist Saroglitazar (SARO) could reduce the increase of inflammatory cytokines and TNFα as a fibrotic marker, but the effects of the combination of QC and CS were stronger. This evidence concerns the gene TNF and metabolic dysfunction-associated steatohepatitis.